Kidney Cancer

October 19, 2020

The FDA is reviewing data from the phase 3 CheckMate-9ER trial, which showed that the combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

October 02, 2020

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.

September 29, 2020

The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.

September 25, 2020

The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

September 25, 2020

Meredith R. Metcalf, MD, discusses recent research evaluating management of clinical T1a RCC in men and women.

September 23, 2020

Investigators also reported that a subgroup of patients with 1 or more target kidney lesions experienced kidney tumor reduction and other benefits from the combination treatment.

September 22, 2020

“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.

September 17, 2020

Renal mass biopsy should be used for patients in whom results would impact management decisions.

August 24, 2020

The combination improved overall survival versus sunitinib in patients with previously untreated advanced RCC.

August 19, 2020

Combination therapy is the first-line standard for metastatic renal cell carcinoma.